EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hepatic CD4 T Cells Predict Hepatocellular Carcinoma Risk on Metabolic Dysfunction‐Associated Steatohepatitis Patients

Emilse Rodriguez, Peter Simon, Sabrina Dhooge, Marina Fernandez iD, Patricia Calafat, María Kurpis, Nicolás Nuñez, Jhon Prieto, Anna Saborowski iD, Arndt Vogel iD, José Daniel Debes, Domingo Cesar Balderramo iD und 2 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Emilse Rodriguez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Privado Centro Médico de Córdoba S.A., Córdoba, Argentina. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Metabolic dysfunction‐associated steatohepatitis (MASH) increasingly drives hepatocellular carcinoma (HCC) development. We characterized inflammatory infiltrates in liver biopsies from MASH patients who developed HCC versus controls to identify predictive immune signatures.

Method

Formalin‐fixed paraffin‐embedded (FFPE) liver biopsies from MASH patients were categorized as pre‐HCC MASH ( n = 10) or control MASH ( n = 13) by the ESCALON consortium. Standardized histological analysis and multiplexed immunohistochemistry were performed targeting CD4, CD8, PD1, PDL1, FoxP3, CXCR6, CD3, CD68, and CD20 using a PhenoImager Fusion scanner. Single‐cell RNA‐seq datasets characterized hepatic CD4 T cell heterogeneity. Clinical parameters measured included ALT, AST, GGT, alkaline phosphatase, platelets, and INR.

Results

Pre‐HCC MASH showed inflammation extending from portal to periportal areas versus portal‐only distribution in controls. Analysis of 291,908 cells revealed significantly higher CD4+ density ( p = 0.0243) and CD4+PD1+ cells ( p = 0.017) in pre‐HCC patients, while CD8+ and regulatory T cell densities remained unchanged. Single‐cell RNA‐seq identified potential phenotypic shifts from Th1 cytotoxicity toward tissue‐repair and Th17 CD4+ T cells in MASH livers. Combined immunological and clinical variables (sex, age, CD4+ T cell numbers, ALT, alkaline phosphatase and platelets) achieved excellent predictive performance (ROC‐AUC = 0.944) for HCC development.

Conclusions

Increase in liver CD4+ T cell infiltration characterizes MASH‐to‐HCC progression. These immune signatures combined with clinical parameters demonstrate remarkable predictive value for identifying high‐risk MASH patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiverCD4-Positive T-LymphocytesFatty LiverNon-alcoholic Fatty Liver DiseaseHumansMaleFemaleMiddle AgedBiopsyAgedCase-Control StudiesRisk Factors

Stichwörter der Autor:innen

CD4+ T cellsHCCINRMASHPD1/PDL1 interactionsblood‐based biomarkers

Autor:innen und Institutionen

  • Hospital Privado Centro Médico de Córdoba S.A., Córdoba, Argentina.
  • Medizinische Hochschule Hannover, Hannover, Germany.
  • Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
  • Centro de enfermedades hepáticas y digestivas (CEHYD), Bogotá, Colombia.
  • Institute for Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medicine, University of Minnesota, Variety Club Research Center, Minneapolis, Minnesota, USA.

ORCID-Profile: Marina Fernandez, Anna Saborowski, Arndt Vogel, Domingo Cesar Balderramo, Andre Boonstra, Pablo Alberto Romagnoli

Förderung

  • European Commission

Zitieren

APA

Rodriguez, E., Simon, P., Dhooge, S., Fernandez, M., Calafat, P., Kurpis, M., Nuñez, N., Prieto, J., Saborowski, A., Vogel, A., Debes, J. D., Balderramo, D. C., Boonstra, A., & Romagnoli, P. A. (2026). Hepatic CD4 T Cells Predict Hepatocellular Carcinoma Risk on Metabolic Dysfunction‐Associated Steatohepatitis Patients. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70159

Vancouver

Rodriguez E, Simon P, Dhooge S, Fernandez M, Calafat P, Kurpis M, et al. Hepatic CD4 T Cells Predict Hepatocellular Carcinoma Risk on Metabolic Dysfunction‐Associated Steatohepatitis Patients. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70159

BibTeX
@article{Rodriguez2026,
  author = {Rodriguez, Emilse and Simon, Peter and Dhooge, Sabrina and Fernandez, Marina and Calafat, Patricia and Kurpis, María and Nuñez, Nicolás and Prieto, Jhon and Saborowski, Anna and Vogel, Arndt and Debes, José Daniel and Balderramo, Domingo Cesar and Boonstra, Andre and Romagnoli, Pablo Alberto},
  title = {Hepatic CD4 T Cells Predict Hepatocellular Carcinoma Risk on Metabolic Dysfunction‐Associated Steatohepatitis Patients},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70159}
}
Kostenlos starten →